Kosten-Nutzen-Analyse neuer Lipidsenker View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-04-25

AUTHORS

Christopher Blaum, Natalie Arnold, Christoph Waldeyer

ABSTRACT

Patients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when considering the cost-effectiveness of a drug are quality adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The lower bounds of the ICER determining the cost-effectiveness of a treatment vary between healthcare systems. The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab are deemed to be cost-effective particularly in patients with high levels of low-density lipoprotein cholesterol (LDL-C) prior to treatment or with a high cardiovascular risk as determined by the presence of defined risk criteria. Similar considerations apply to the PCSK9 small interfering RNA (siRNA) inclisiran. Administration of bempedoic acid is deemed cost-effective especially in patients with statin intolerance. Eicosapentaenoic acid is deemed cost-effective overall, although the data with respect to the exact placebo-controlled efficacy are still inconclusive. More... »

PAGES

236-243

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05116-8

DOI

http://dx.doi.org/10.1007/s00059-022-05116-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147364825

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35467096


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticholesteremic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "PCSK9 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proprotein Convertase 9", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Kardiologie, Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum Hamburg, Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr.\u00a052, 20246, Hamburg, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.13648.38", 
          "name": [
            "Klinik f\u00fcr Kardiologie, Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum Hamburg, Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr.\u00a052, 20246, Hamburg, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blaum", 
        "givenName": "Christopher", 
        "id": "sg:person.013676665330.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676665330.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung e.\u202fV. (DZHK e.\u202fV.), Standort Hamburg/Kiel/L\u00fcbeck, Hamburg, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr Kardiologie, Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum Hamburg, Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr.\u00a052, 20246, Hamburg, Deutschland", 
            "Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung e.\u202fV. (DZHK e.\u202fV.), Standort Hamburg/Kiel/L\u00fcbeck, Hamburg, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arnold", 
        "givenName": "Natalie", 
        "id": "sg:person.014526547155.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014526547155.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung e.\u202fV. (DZHK e.\u202fV.), Standort Hamburg/Kiel/L\u00fcbeck, Hamburg, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik f\u00fcr Kardiologie, Universit\u00e4res Herz- und Gef\u00e4\u00dfzentrum Hamburg, Universit\u00e4tsklinikum Hamburg-Eppendorf, Martinistr.\u00a052, 20246, Hamburg, Deutschland", 
            "Deutsches Zentrum f\u00fcr Herz-Kreislauf-Forschung e.\u202fV. (DZHK e.\u202fV.), Standort Hamburg/Kiel/L\u00fcbeck, Hamburg, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Waldeyer", 
        "givenName": "Christoph", 
        "id": "sg:person.01076476665.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076476665.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ncomms13457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047008360", 
          "https://doi.org/10.1038/ncomms13457"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-25", 
    "datePublishedReg": "2022-04-25", 
    "description": "Patients with atherosclerotic cardiovascular disease have a\u00a0high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a\u00a0central and direct cause of this, with a\u00a0frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when considering the cost-effectiveness of a\u00a0drug are quality adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The lower bounds of the ICER determining the cost-effectiveness of a\u00a0treatment vary between healthcare systems. The proprotein convertase subtilisin-kexin type\u00a09 (PCSK9) inhibitors alirocumab and evolocumab are deemed to be cost-effective particularly in patients with high levels of low-density lipoprotein cholesterol (LDL-C) prior to treatment or with a\u00a0high cardiovascular risk as determined by the presence of defined risk criteria. Similar considerations apply to the PCSK9 small interfering RNA (siRNA) inclisiran. Administration of bempedoic acid is deemed cost-effective especially in patients with statin intolerance. Eicosapentaenoic acid is deemed cost-effective overall, although the data with respect to the exact placebo-controlled efficacy are still inconclusive.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05116-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "incremental cost-effectiveness ratio", 
      "proprotein convertase subtilisin kexin type", 
      "low-density lipoprotein cholesterol", 
      "lipid-lowering substances", 
      "placebo-controlled efficacy", 
      "subsequent cardiovascular events", 
      "high cardiovascular risk", 
      "atherosclerotic cardiovascular disease", 
      "optimal drug treatment", 
      "cost-effectiveness ratio", 
      "cost-effectiveness analysis", 
      "cardiovascular events", 
      "cardiovascular risk", 
      "statin intolerance", 
      "lipoprotein cholesterol", 
      "bempedoic acid", 
      "cardiovascular disease", 
      "drug treatment", 
      "cost-effective overall", 
      "high risk", 
      "treatment varies", 
      "life years", 
      "patients", 
      "eicosapentaenoic acid", 
      "healthcare system", 
      "residual risk", 
      "treatment", 
      "risk", 
      "direct cause", 
      "risk criteria", 
      "alirocumab", 
      "evolocumab", 
      "inclisiran", 
      "dyslipidemia", 
      "high levels", 
      "statins", 
      "ezetimibe", 
      "PCSK9", 
      "disease", 
      "cholesterol", 
      "intolerance", 
      "administration", 
      "drugs", 
      "efficacy", 
      "Overall", 
      "cause", 
      "frequent failure", 
      "guidelines", 
      "failure", 
      "acid", 
      "years", 
      "high cost", 
      "levels", 
      "criteria", 
      "important variables", 
      "Kosten-Nutzen", 
      "substances", 
      "events", 
      "presence", 
      "use", 
      "target values", 
      "data", 
      "quality", 
      "variables", 
      "ratio", 
      "types", 
      "varies", 
      "analysis", 
      "Similar considerations", 
      "values", 
      "consideration", 
      "respect", 
      "cost", 
      "system", 
      "order", 
      "bounds", 
      "lower bounds"
    ], 
    "name": "Kosten-Nutzen-Analyse neuer Lipidsenker", 
    "pagination": "236-243", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147364825"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05116-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35467096"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05116-8", 
      "https://app.dimensions.ai/details/publication/pub.1147364825"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_950.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05116-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05116-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05116-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05116-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05116-8'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      21 PREDICATES      111 URIs      102 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05116-8 schema:about N1f28ab80efeb41cfabf981d7912377bd
2 N5f669b36ec7d410fb2167f33366ef113
3 N6df844230dc54d748dc44fb8723ba286
4 Na274db824cae465189bc660464c333e3
5 Na448827b05674a60869a528035de215e
6 Nbc90ff9ce931496bbdbbd88175b69fe7
7 Nd68b95d68d0e41e69807f7b4e1734933
8 Ndc520d7dd71343b6959bb0208e33438e
9 anzsrc-for:11
10 anzsrc-for:1102
11 schema:author N0dfa1ccaaaad40b1b99d1b201a171ce1
12 schema:citation sg:pub.10.1038/ncomms13457
13 schema:datePublished 2022-04-25
14 schema:datePublishedReg 2022-04-25
15 schema:description Patients with atherosclerotic cardiovascular disease have a high risk for subsequent cardiovascular events despite optimal drug treatment including statins and ezetimibe. Dyslipidemia represents a central and direct cause of this, with a frequent failure to achieve the target values recommended in the guidelines. New lipid-lowering substances are increasingly becoming available for treatment of this residual risk. Due to their high cost, cost-effectiveness analyses are required in order to justify their use. Important variables when considering the cost-effectiveness of a drug are quality adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The lower bounds of the ICER determining the cost-effectiveness of a treatment vary between healthcare systems. The proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab are deemed to be cost-effective particularly in patients with high levels of low-density lipoprotein cholesterol (LDL-C) prior to treatment or with a high cardiovascular risk as determined by the presence of defined risk criteria. Similar considerations apply to the PCSK9 small interfering RNA (siRNA) inclisiran. Administration of bempedoic acid is deemed cost-effective especially in patients with statin intolerance. Eicosapentaenoic acid is deemed cost-effective overall, although the data with respect to the exact placebo-controlled efficacy are still inconclusive.
16 schema:genre article
17 schema:isAccessibleForFree false
18 schema:isPartOf N64b1d019319342d99aa40a554a2a83d5
19 Na8cd9338fb0e405493854bd23b4baa45
20 sg:journal.1087175
21 schema:keywords Kosten-Nutzen
22 Overall
23 PCSK9
24 Similar considerations
25 acid
26 administration
27 alirocumab
28 analysis
29 atherosclerotic cardiovascular disease
30 bempedoic acid
31 bounds
32 cardiovascular disease
33 cardiovascular events
34 cardiovascular risk
35 cause
36 cholesterol
37 consideration
38 cost
39 cost-effective overall
40 cost-effectiveness analysis
41 cost-effectiveness ratio
42 criteria
43 data
44 direct cause
45 disease
46 drug treatment
47 drugs
48 dyslipidemia
49 efficacy
50 eicosapentaenoic acid
51 events
52 evolocumab
53 ezetimibe
54 failure
55 frequent failure
56 guidelines
57 healthcare system
58 high cardiovascular risk
59 high cost
60 high levels
61 high risk
62 important variables
63 inclisiran
64 incremental cost-effectiveness ratio
65 intolerance
66 levels
67 life years
68 lipid-lowering substances
69 lipoprotein cholesterol
70 low-density lipoprotein cholesterol
71 lower bounds
72 optimal drug treatment
73 order
74 patients
75 placebo-controlled efficacy
76 presence
77 proprotein convertase subtilisin kexin type
78 quality
79 ratio
80 residual risk
81 respect
82 risk
83 risk criteria
84 statin intolerance
85 statins
86 subsequent cardiovascular events
87 substances
88 system
89 target values
90 treatment
91 treatment varies
92 types
93 use
94 values
95 variables
96 varies
97 years
98 schema:name Kosten-Nutzen-Analyse neuer Lipidsenker
99 schema:pagination 236-243
100 schema:productId N5d053c77632e43af888b468e15097b6b
101 N76e5e2a39ec142c293de8ad0a0b5d2f0
102 Ncea9db3c7ea646fbb90a0bdf943d8822
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147364825
104 https://doi.org/10.1007/s00059-022-05116-8
105 schema:sdDatePublished 2022-09-02T16:08
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher N602613b58a794d4888b531f372eb5cb8
108 schema:url https://doi.org/10.1007/s00059-022-05116-8
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N0dfa1ccaaaad40b1b99d1b201a171ce1 rdf:first sg:person.013676665330.81
113 rdf:rest Na47dfe6584d34aafa84c25b95fe14d66
114 N1f28ab80efeb41cfabf981d7912377bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Antibodies, Monoclonal
116 rdf:type schema:DefinedTerm
117 N5d053c77632e43af888b468e15097b6b schema:name pubmed_id
118 schema:value 35467096
119 rdf:type schema:PropertyValue
120 N5db9fd0db65f401a856e4177a0320213 rdf:first sg:person.01076476665.47
121 rdf:rest rdf:nil
122 N5f669b36ec7d410fb2167f33366ef113 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Proprotein Convertase 9
124 rdf:type schema:DefinedTerm
125 N602613b58a794d4888b531f372eb5cb8 schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 N64b1d019319342d99aa40a554a2a83d5 schema:issueNumber 3
128 rdf:type schema:PublicationIssue
129 N6df844230dc54d748dc44fb8723ba286 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Cholesterol, LDL
131 rdf:type schema:DefinedTerm
132 N76e5e2a39ec142c293de8ad0a0b5d2f0 schema:name dimensions_id
133 schema:value pub.1147364825
134 rdf:type schema:PropertyValue
135 Na274db824cae465189bc660464c333e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Anticholesteremic Agents
137 rdf:type schema:DefinedTerm
138 Na448827b05674a60869a528035de215e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cost-Benefit Analysis
140 rdf:type schema:DefinedTerm
141 Na47dfe6584d34aafa84c25b95fe14d66 rdf:first sg:person.014526547155.27
142 rdf:rest N5db9fd0db65f401a856e4177a0320213
143 Na8cd9338fb0e405493854bd23b4baa45 schema:volumeNumber 47
144 rdf:type schema:PublicationVolume
145 Nbc90ff9ce931496bbdbbd88175b69fe7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 Ncea9db3c7ea646fbb90a0bdf943d8822 schema:name doi
149 schema:value 10.1007/s00059-022-05116-8
150 rdf:type schema:PropertyValue
151 Nd68b95d68d0e41e69807f7b4e1734933 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name PCSK9 Inhibitors
153 rdf:type schema:DefinedTerm
154 Ndc520d7dd71343b6959bb0208e33438e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
161 schema:name Cardiorespiratory Medicine and Haematology
162 rdf:type schema:DefinedTerm
163 sg:journal.1087175 schema:issn 0340-9937
164 1615-6692
165 schema:name Herz
166 schema:publisher Springer Nature
167 rdf:type schema:Periodical
168 sg:person.01076476665.47 schema:affiliation grid-institutes:None
169 schema:familyName Waldeyer
170 schema:givenName Christoph
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076476665.47
172 rdf:type schema:Person
173 sg:person.013676665330.81 schema:affiliation grid-institutes:grid.13648.38
174 schema:familyName Blaum
175 schema:givenName Christopher
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013676665330.81
177 rdf:type schema:Person
178 sg:person.014526547155.27 schema:affiliation grid-institutes:None
179 schema:familyName Arnold
180 schema:givenName Natalie
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014526547155.27
182 rdf:type schema:Person
183 sg:pub.10.1038/ncomms13457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047008360
184 https://doi.org/10.1038/ncomms13457
185 rdf:type schema:CreativeWork
186 grid-institutes:None schema:alternateName Deutsches Zentrum für Herz-Kreislauf-Forschung e. V. (DZHK e. V.), Standort Hamburg/Kiel/Lübeck, Hamburg, Deutschland
187 schema:name Deutsches Zentrum für Herz-Kreislauf-Forschung e. V. (DZHK e. V.), Standort Hamburg/Kiel/Lübeck, Hamburg, Deutschland
188 Klinik für Kardiologie, Universitäres Herz- und Gefäßzentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland
189 rdf:type schema:Organization
190 grid-institutes:grid.13648.38 schema:alternateName Klinik für Kardiologie, Universitäres Herz- und Gefäßzentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland
191 schema:name Klinik für Kardiologie, Universitäres Herz- und Gefäßzentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...